NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NSABP Foundation Inc
Fudan University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Peking University
Shanghai Changzheng Hospital
Fondazione del Piemonte per l'Oncologia